株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の抗レトロウイルス療法市場:2017年~2021年

Global Antiretroviral Therapy Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 580013
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
世界の抗レトロウイルス療法市場:2017年~2021年 Global Antiretroviral Therapy Market 2017-2021
出版日: 2017年11月13日 ページ情報: 英文 81 Pages
概要

世界の抗レトロウイルス療法市場は、2017年から2021年の予測期間中、CAGRが2.64%成長する見込みとなっております。

当レポートでは、世界の抗レトロウイルス療法市場について調査分析を行い、市場概要、市場動向、市場規模などについて考察するとともに、薬物クラス別、地域別に市場を分析、ベンダーの状況などについて包括的に分析し、まとめています。

第1章 エグゼクティブサマリー

第2章 調査の範囲

第3章 調査方法

第4章 イントロダクション

第5章 疾病の概要

第6章 市場の状況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 パイプラインの状況

第8章 市場セグメンテーション:薬物クラス別

  • 多クラス混合製品
  • NRTI
  • インテグラーゼ阻害剤
  • NNRTI
  • その他

第9章 地域の状況

  • 地域比較
  • 南北アメリカ
  • 欧州/中東/アフリカ
  • アジア太平洋地域
  • 市場機会

第10章 決定の枠組み

第11章 促進因子と課題

第12章 市場動向

  • 主なパイプライン
  • 高度な製剤
  • 資金調達と治療の取り組み

第13章 ベンダーの状況

  • ベンダーの状況

第14章 主要ベンダー分析

  • Gilead
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • F. Hoffmann-La Roche
  • その他のベンダー

第15章 付録

別紙一覧

図表
  • Exhibit 01: Global ART market
  • Exhibit 02: Global ART market 2016-2021 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Pipeline landscape by development phase
  • Exhibit 05: Key clinical trials
  • Exhibit 06: Global ART market by drug class 2016
  • Exhibit 07: Global ART market by drug class 2021
  • Exhibit 08: Global ART market by multiclass combination products 2016-2021 ($ millions)
  • Exhibit 09: Global ART market by NRTIs 2016-2021 ($ millions)
  • Exhibit 10: Global ART market by integrase inhibitors 2016-2021 ($ millions)
  • Exhibit 11: Global ART market by NNRTIs 2016-2021 ($ millions)
  • Exhibit 12: Global ART market by others 2016-2021 ($ millions)
  • Exhibit 13: Global ART market: Regional landscape
  • Exhibit 14: Regional comparison
  • Exhibit 15: ART market in Americas 2016-2021 ($ millions)
  • Exhibit 16: ART market in Americas - Year over year growth 2017-2021
  • Exhibit 17: ART market in EMEA 2016-2021 ($ millions)
  • Exhibit 18: ART market in EMEA - Year over year growth 2017-2021
  • Exhibit 19: ART market in APAC 2016-2021 ($ millions)
  • Exhibit 20: ART market in APAC - Year over year growth 2017-2021
  • Exhibit 21: Gilead: Key highlights
  • Exhibit 22: Gilead: Strength assessment
  • Exhibit 23: Gilead: Strategy assessment
  • Exhibit 24: Gilead: Opportunity assessment
  • Exhibit 25: ViiV Healthcare: Key highlights
  • Exhibit 26: ViiV Healthcare: Strength assessment
  • Exhibit 27: ViiV Healthcare: Strategy assessment
  • Exhibit 28: ViiV Healthcare: Opportunity assessment
  • Exhibit 29: Janssen Pharmaceuticals: Key highlights
  • Exhibit 30: Janssen Pharmaceuticals: Strength assessment
  • Exhibit 31: Janssen Pharmaceuticals: Strategy assessment
  • Exhibit 32: Janssen Pharmaceuticals: Opportunity assessment
  • Exhibit 33: F. Hoffmann-La Roche: Key highlights
  • Exhibit 34: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 35: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 36: F. Hoffmann-La Roche: Opportunity assessment
目次
Product Code: IRTNTR15445

About Antiretroviral Therapy

The antiretroviral therapy (ART) market is primarily related to the treatment of human immunodeficiency virus (HIV) infection. Antiretroviral drugs are usually taken in combination to prevent the growth of the virus, which slows the growth of HIV infection. The major drivers for the ART market include the rising awareness of retroviral infection, aggressive innovation in diagnostic techniques, the introduction of novel drugs through significant investments made in R&D, and high unmet needs in the retrovirus infection treatment domain.

Technavio's analysts forecast the global antiretroviral therapy market to grow at a CAGR of 2.64% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global antiretroviral therapy market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Antiretroviral Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Gilead
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • F. Hoffmann-La Roche

Other Prominent Vendors

  • Abbvie
  • Boehringer Ingelheim
  • Bionor Pharma
  • Vertex Pharmaceuticals
  • Mylan

Market driver

  • Rising awareness of retroviral infection
  • For a full, detailed list, view our report

Market challenge

  • High cost of antiretroviral drugs
  • For a full, detailed list, view our report

Market trend

  • Significant pipeline
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: DISEASE OVERVIEW

PART 06: MARKET LANDSCAPE

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY DRUG CLASS

  • Multiclass combination products
  • NRTIs
  • Integrase inhibitors
  • NNRTIs
  • Others

PART 09: REGIONAL LANDSCAPE

  • Regional comparison
  • ART market in Americas
  • ART market in EMEA
  • ART market in APAC
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Significant pipeline
  • Advanced formulations
  • Funding and treatment initiatives

PART 13: VENDOR LANDSCAPE

  • Vendor landscape

PART 14: KEY VENDOR ANALYSIS

  • Gilead
  • ViiV Healthcare
  • Janssen Pharmaceuticals
  • F. Hoffmann-La Roche
  • Other prominent vendors

PART 15: APPENDIX

  • List of abbreviations
Back to Top